pharmaphorum
JANUARY 26, 2023
Protein prediction algorithms will reach their potential Proteomics has long been hindered by inaccurate or incomplete RNA sequences – with resultant predictive models built from RNA proving inaccurate. Just one mutation can lead to a complete change in protein formation. So, when it comes to proteomics, accuracy is vital.
pharmaphorum
AUGUST 4, 2022
Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Today, the landscape of genomic testing and research is rapidly progressing, with significant scientific and technological advances driving a paradigm shift in the understanding of oncology at a molecular level.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 14, 2020
Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. In reality, finishing the human genome was the first step of what is a long journey.”. Now, however, the field is changing with respect to genomic medicine.
Pharmaceutical Technology
AUGUST 26, 2008
. “The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .
pharmaphorum
SEPTEMBER 9, 2020
Everything the 100,000 Genomes Project does has to be rubber-stamped by the patients”. At the time, the Sanger Institute was working on the Deciphering Developmental Disorders study (DDD), which looked at the approximately 1-2% of the genome that is responsible for making proteins in patients with rare diseases.
Roots Analysis
AUGUST 28, 2022
Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. The trend is unlikely to change in the foreseen future. Concluding Remarks.
pharmaphorum
SEPTEMBER 9, 2020
Everything the 100,000 Genomes Project does has to be rubber-stamped by the patients”. At the time, the Sanger Institute was working on the Deciphering Developmental Disorders study (DDD), which looked at the approximately 1-2% of the genome that is responsible for making proteins in patients with rare diseases.
Expert insights. Personalized for you.
129 
Let's personalize your content